# Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma

> **NCT07213934** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Cincinnati** · enrollment: 40 (estimated)

## Conditions studied

- Head and Neck Cancer
- Recurrent Head and Neck Squamous Cell Carcinoma

## Interventions

- **RADIATION:** Proton therapy
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07213934
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-08
- **Primary completion:** 2030-12
- **Final completion:** 2031-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07213934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07213934, "Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07213934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*